Sobi Pharmaceuticals (General Brand)

Swedish Orphan Biovitrum AB, commonly known as Sobi, is an international biopharmaceutical company dedicated to rare diseases. The company was headquartered in Sweden following the 2010 merger between Biovitrum and Swedish Orphan International. Sobi focuses on providing innovative treatments in the areas of haematology, immunology, and specialty care. Their product portfolio includes advanced therapies like Vonjo (pacritinib) for myelofibrosis, which was integrated into their offerings through strategic acquisitions like that of CTI BioPharma in 2023.

While the company is headquartered in Stockholm, its manufacturing strategy involves a complex global supply chain. Sobi utilizes both its own specialized facilities and partnerships with Contract Manufacturing Organizations (CMOs) across Europe and North America to ensure the production of complex biologics and niche medicines. As a publicly traded entity on the Nasdaq Stockholm, Sobi remains a major independent player in the rare disease sector, continuously expanding its global footprint through R&D and targeted corporate acquisitions.